Content about Biogen Idec

March 27, 2013
FDA approves new MS drug

The Food and Drug Administration has approved a new treatment for multiple sclerosis made by Biogen Idec, the agency said.

March 11, 2013
Early detection of PML in multiple sclerosis patients treated with immune-suppressing drugs may improve survival

Early detection of a deadly brain infection that sometimes arises due to treatment of autoimmune disorders with immune-suppressing biotech drugs may improve survival, according to a new study.

February 26, 2013
Reports: Elan not responding to acquisition offer from Royalty Pharma

A privately owned drug maker in New York is offering $6.5 billion for Irish drug maker Elan Corp., but hasn't heard back from it, according to published reports.

February 8, 2013
Elan sells Tysabri rights to Biogen Idec

Elan will sell the rights to its drug for multiple sclerosis to partnering company Biogen Idec for $3.25 billion plus royalties, the Irish drug maker said.

January 28, 2013
FDA accepts application for Genzyme MS drug

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

January 7, 2013
Biogen Idec hopes treatment will be first advance in hemophilia B treatment in 15 years

Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

January 3, 2013
Experimental ALS drug fails in trial

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

December 18, 2012
Most prescribers would pick biosimilar RA drugs

A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

February 29, 2012
FDA approves Biogen Idec's Avonex Pen, dose titration regimen

The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug.

February 15, 2012
Biogen Idec to acquire Stromedix

Drug maker Biogen Idec plans to spend up to more than $560 million to buy a company developing treatments for organ failure.

January 30, 2012
Biogen Idec appoints EVP human resources

Biogen Idec has appointed a former Lenovo executive to serve as its EVP human resources.

January 5, 2012
Biogen Idec, Isis to develop spinal muscular atrophy drug

Biogen Idec and Isis Pharmaceuticals will work together on a drug invented by Isis for spinal muscular atrophy, the two companies said.

October 12, 2011
Teva's Copaxone reduced brain volume loss in patients, according to study

Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.

September 29, 2011
Biogen Idec appoints EVP global commercial operations

Biogen Idec has appointed Tony Kingsley as its new EVP global commercial operations.

July 28, 2011
Biogen Idec expands MS ActiveSource

Biogen Idec has expanded its online resource for patients living with multiple sclerosis to include new resources and support programs.

May 25, 2011
Biogen Idec introduces Women in MS educational initiative

Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

December 21, 2010
Biogen acquires rights to neuro disease programs

In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.

November 3, 2010
Biogen Idec, Cardiokine terminate lixivaptan agreement

Swiss drug maker Biogen Idec and U.S. drug maker Cardiokine have terminated an agreement to...

September 28, 2010
Decision Resources: Crohn's disease drug market will increase 31% by 2019

The drug market for Crohn's disease treatments will see moderate growth over the next decade,...

September 8, 2010
GSK, Genmab begin late-stage clinical trial for cancer drug

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

August 18, 2010
Biogen Idec inks ALS treatment deal with Knopp

Swiss drug maker Biogen Idec will develop and commercialize an investigational drug as a treatment...

August 8, 2010
Dr. Reddy's launches Cresp

Generic drug maker Dr. Reddy’s has launched in India the world’s first follow-on version of...

July 7, 2010
Sanofi-Aventis to buy another drug maker?

A big-ticket acquisition could be in the works for French drug maker Sanofi-Aventis, according to...

May 24, 2010
Report: Teva recruits patients for Rituxan biosimilar trial

Generic drug maker Teva Pharmaceutical Industries isn’t holding back in its effort to push into...

May 23, 2010
Biogen Idec, Abbott enroll patients in late-stage trial for MS drug

Swiss biotech company Biogen Idec and U.S. drug maker Abbott have begun enrolling patients in...

© 2013 Drug Store News. All Rights Reserved.